CASE-BASED LEARNING

A woman with breathlessness: a practical approach to diagnosis and management

*Alan Kaplan1, Kevin Gruffydd-Jones2, Frederik van Gemert3, Bruce J Kirenga4, Andrew RL Medford5

1 Family Physician Airways Group of Canada, Richmond Hill, Ontario, Canada
2 General Practitioner, Box Surgery, Box, Wiltshire, UK
3 Department of General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 Department of Medicine, School of Medicine, Makerere University, Kampala, Uganda
5 Consultant & Honorary Senior Lecturer in Thoracic Medicine & Interventional Pulmonology, North Bristol Lung Centre & University of Bristol, Southmead Hospital, Bristol, UK

Commissioned article; externally peer-reviewed; received 30th September 2013; accepted 26th October 2013; online 23rd November 2013

Abstract
Worsening breathless in a patient with severe chronic obstructive pulmonary disease (COPD) is a common diagnostic and management challenge in primary care. A systematic approach to history-taking and examination combined with targeted investigation of pulmonary, cardiovascular, thromboembolic and systemic causes is essential if co-morbidities are to be identified and managed. Distinguishing between heart failure and COPD is a particular challenge as symptoms and signs overlap. In low and middle income countries additional priorities are the detection of infections such as tuberculosis and human immunodeficiency virus (HIV). Clinicians need to be alert to the possibility of atypical presentations (such as pain-free variants of angina) and less common conditions (including chronic thromboembolic pulmonary hypertension) in order not to overlook important potentially treatable conditions.

© 2013 Primary Care Respiratory Society UK. All rights reserved.

Keywords Breathlessness, dyspnoea, diagnosis, management

Clinical Scenario
A 52 year old lady consults her family doctor complaining of breathlessness. You can see from her medical record that she has chronic obstructive pulmonary disease (COPD) for which she uses a salbutamol inhaler when needed. Two years ago she had an FEV1 of 45% predicted and a Medical Research Council dyspnoea score of 3. She has smoked since her late teens, but she had attended a well woman clinic several months ago when she requested help with quitting smoking. She had a BMI of 27 at that consultation and a blood pressure of 145/85. Until recently she has not been too troubled by breathlessness. Over the last few months, however, she has noticed that climbing the stairs at work is making her short of breath. Over the weekend she had to abandon a walk with the grandchildren because her breathing was so uncomfortable, and her family persuaded her that she needed to see her doctor.

Respiratory or cardiac?
Congestive Heart Failure (CHF) and chronic obstructive pulmonary disease (COPD) coexist in about 20% of our patients, linked by a common pathophysiology of low-grade systemic inflammation. Two years ago this woman had severe COPD, and her severity is likely to be worse now as she has continued to smoke. She may also have developed CHF.

Distinguishing COPD and CHF
Classic historical and investigative findings of CHF may overlap or be altered in a patient with COPD which can make the distinction difficult. Symptoms common to both conditions include dyspnoea, cough, exercise intolerance, fatigue, muscle weakness, disturbed sleep, anorexia, low mood, and anxiety. Differentiating questions for CHF include ankle swelling, chest pain, nocturia, orthopnoea and paroxysmal nocturnal dyspnoea.

Examination findings for COPD include barrel chest, hyperinflation, and wheezing. Those of heart failure include jugular venous distension, edema, and murmurs.
venous distension, ankle oedema, third and fourth heart sounds and hepatomegaly. These signs, however, can be obscured. Stigmata of right ventricular failure (cor pulmonale), which complicates advanced COPD, can cause jugular venous distension, peripheral oedema, and hepatomegaly. Lung hyperinflation causes hepatic displacement which mimics left heart failure without the presence of cardiomegaly and the auscultation of rales or a third heart sound.

**Investigations**

A summary of appropriate investigations is given in Table 1, with the classical results for COPD and CHF. However, our patient already has COPD and this may affect classical appearances: for example, radiological evidence of CHF can be influenced by the hyperinflation of COPD. Acoustic windows may be impeded by air trapping in pulmonary disease, thus affecting the quality of echocardiographic images. B-type natriuretic peptide (BNP) is substantially elevated in acute heart failure but may also be raised in cor pulmonale, and levels overlap with those in stable CHF (see figure 1). Normal BNP thus excludes CHF, but a raised level does not confirm the diagnosis.

Choosing appropriate therapy in a patient with CHF with co-existent COPD is often uncertain; the available evidence derives from randomised clinical trials from which patients with comorbidity have been excluded, or is based on retrospective studies and/or subgroup analysis of single disease trials.

**Managing the co-morbidities of COPD and CHF**

Whether our patient has worsening COPD or has developed CHF, her management will need to include advice and support to help her quit smoking.

| Table 1. Investigation of COPD and CHF |
|-------------------------------|----------------------------------|----------------------------------|----------------------------------|
| **Investigation**              | **Result in COPD**               | **Result in CHF**                | **Notes about the overlap**      |
| CXR                            | Hyperinflation, Vascular remodelling | Cardiomegaly, Vascular redistribution, Alveolar shadowing | Pulmonary vascular remodelling in those with COPD can mimic (upper lobe venous diversion) or mask pulmonary oedema (asymmetric, regional, and reticular patterns). Chest hyperinflation will falsely reduce the cardiothoracic ratio |
| Electrocardiography (ECG)      | Cor pulmonale results in a range of ECG abnormalities including right bundle branch block and right ventricular hypertrophy | Check for rhythm disturbances and signs of ischaemic heart disease | The presence of ECG signs of cor pulmonale are indicative of a poor prognosis |
| Echocardiography               | Assess cardiac function          | Systolic vs diastolic function, Valvular issues | Acoustic windows may be impeded by air trapping in pulmonary disease, affecting quality of images as often as 10% in stable primary care patients with COPD, 35% in severe disease, and 50% in very severe airflow obstruction. |
| B-type natriuretic peptide (BNP)| In stable disease, should be <100, but BNP levels can be increased in patients with COPD (and many other conditions) | BNP is secreted by the left ventricle (LV) in response to volume elevated LV pressure; will differentiate cardiac from pulmonary cause of dyspnea, especially for excluding CHF in subjects with acute dyspnoea. | Normal levels exclude CHF, but raised levels can have many causes. Cor pulmonale is associated with an intermediate elevation of BNP typically ranging from 100 to 500 pg/mL. Levels <100 and >500 pg/mL have high negative and positive predictive values, respectively, for HF. See Figure 1 |
| Spirometry                     | Obstruction. Diagnostic is post BD ratio of FEV1/FVC <70% | Interstitial and alveolar oedema cause compression and obstruction of the airways in patients with decompensated CHF contrasting with restrictive defects when CHF is stable | Potential misdiagnosis and overestimation of COPD severity. With diuresis, mean FEV1 improves by up to 35% and often returns to normal. |

Choosing appropriate therapy in a patient with CHF and COPD is often uncertain; the available evidence derives from randomised clinical trials from which patients with comorbidity have been excluded, or is based on retrospective studies and/or subgroup analysis of single disease trials.

Pharmacologic management of CHF includes angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARBs) to assist in wall remodelling, diuretics to reduce fluid overload, digoxin for rate-related issues, and β-blockers to improve prognosis and reduce mortality in all patients with systolic dysfunction. Pharmacological therapy of COPD includes maximal...
bronchodilation (including with β₂-agonists) and anti-inflammatory treatments to help reduce exacerbations.

**a) Cardiovascular drugs in people with COPD**

Some interactions are positive: ACE inhibitors and ARBs may also decrease pulmonary inflammation and vascular constriction.\(^\text{17}\) Others are potentially harmful: intensive diuretic therapy may cause metabolic alkalosis which theoretically could interfere with the respiratory drive of COPD patients, causing hypoventilation with subsequent worsening of hypercapnia, though this is rarely reported at standard doses.\(^\text{18}\) There is evidence that statins may reduce morbidity and/or mortality in COPD patients.\(^\text{19}\)

β-blocker therapy is recommended,\(^\text{20}\) but underused,\(^\text{21,22}\) in patients with coexistent COPD and heart failure for fear of precipitating bronchospasm.\(^\text{23}\) β-blockers, however, have proved to be safe and generally well tolerated in patients with pulmonary disease.\(^\text{24,25}\) Cardiac-selective β₁-blockers\(^\text{26}\) such as nebivolol, bisoprolol and atenolol\(^\text{27}\) can be safely used to treat heart failure in patients with respiratory disease,\(^\text{28}\) potentially even in those with reversible obstruction.\(^\text{25}\) A pooled relative risk of mortality related to β-blockers in a recent meta-analysis of COPD patients was 0.69 (95% CI 0.62–0.78).\(^\text{29}\)

**b) COPD drugs in people with CHF**

Inhaled bronchodilators (antimuscarinics and β₂-agonists) in COPD patients with concomitant CHF cause some concerns.\(^\text{3}\) Short-acting β₂-agonists (SABAs) increase myocardial oxygen consumption due to tachycardia\(^\text{30}\) and a few studies have shown an increase in mortality and heart failure exacerbations.\(^\text{31,32}\) Reassuringly, however, a large study of long-acting β₂-agonists (LABAs) in people with COPD did not increase adverse cardiovascular events.\(^\text{33}\) Further large trials of LABA with and without inhaled steroids are on-going, examining all-cause mortality in patients with moderate COPD and co-morbid cardiovascular disease.\(^\text{34}\)

There continues to be debate that short-acting antimuscarinics (SAMA) may have some cardiovascular toxicity.\(^\text{35}\) The safety of long-acting antimuscarinics (LAMAs) has been questioned after trials with tiotropium delivered via the Respimat soft mist inhaler showed an increased mortality in the intervention group compared with placebo.\(^\text{36}\) In contrast, a trial with the dry powder inhaler demonstrated fewer deaths in the tiotropium group.\(^\text{37}\) A Cochrane review concluded that non-fatal serious adverse events were less frequent with tiotropium than with LABA.\(^\text{38}\) A recent study comparing tiotropium by Handihaler (dry powder) versus Respimat (fine mist) did not show any difference in cardiovascular outcomes.\(^\text{39}\)

**A practical approach to managing our patient**

So, how might we approach this woman who presents to our primary care office today?

- Assess for proper COPD inhaler device technique and adherence, and consider a trial of stepping up treatment.
- Convince ourselves clinically using the Well’s score that DVT or PE is unlikely.\(^\text{40}\)
- Do a full examination and look for evidence of CHF, albeit this could be difficult to detect.
- Arrange a chest X-ray (CXR) and an electrocardiogram (ECG)
- Consider repeating spirometry, but recognise that some obstruction may be related to fluid overload, making it best to do the test when patients are clinically euvoalaemic.\(^\text{41}\)
- Order some blood tests including a full blood count, kidney function, thyroid function and BNP measurement if it is available.

If CHF is possible, begin therapy with some diuretics and most importantly, arrange follow-up. Asking the patient to do daily weights at home to establish their dry weight will assist long term follow-up. If diuresis helps, arrange for an echocardiogram, institute ACE-I or ARB therapy and consider β-blockers and statins. Referral may be necessary for those who do not respond, worsen, have diagnostic issues, or are suspected of cardiac ischaemia.

**What else might be the problem?**

Other principal causes of chronic breathlessness (i.e. breathlessness occurring over a few months) are shown in Table 2.

**History**

The aims of accurate history taking are to determine the cause of breathlessness, ascertain the impact of the breathlessness on the patient’s life, and understand the patient’s views to facilitate future management decisions. In addition to cardiovascular causes, there are a number of other specific conditions to consider:

- A major cause of mortality in COPD patients is lung cancer.\(^\text{42}\)
- “Red flag” symptoms include haemoptysis and/or persistent (i.e. lasting more than 3 weeks) symptoms of cough, chest/shoulder pain, breathlessness, weight loss or hoarseness. A normal CXR does not exclude lung cancer, so if the patient is in a high risk group (i.e. over the age of 40, and a smoker or ex-smoker) they should be referred urgently to a chest physician.\(^\text{43}\)
- The presence of a persistent cough, with or without haemoptysis, might be a presentation of tuberculosis in a patient residing in or travelling from an area where the disease is endemic.\(^\text{44}\)

**Table 2. Causes of chronic breathlessness in an adult**

| Cause                      | Specific examples                                      |
|----------------------------|--------------------------------------------------------|
| **Pulmonary causes**       | TB, Legionella                                        |
| Infection                  | COPD, Asthma, Bronchial neoplasm                      |
| Obstructive Airways Disease| Pleural effusion, Mesothelioma                        |
| Pleural Disease            | Pulmonary infiltrates (neoplastic, sarroid)           |
| Parenchymal Disease        | Autoimmune diseases (g SLE)                           |
|                            | Pulmonary fibrosis                                     |
|                            | Extrinsic allergic alveolitis                          |
|                            | Pneumococcosis                                         |
| **Cardiovascular causes**  | Cardiac disease, CHF                                   |
|                            | Thromboembolism                                        |
|                            | Pulmonary hypertension                                 |
| **Weight gain**            | Obesity, oedema, hypothyroidism.                       |
| **Drug induced**           | Methotrexate, non-steroidal anti-inflammatory drugs, amiodarone |
| **“Systemic”**             | Anaemia, Thyrotoxicosis                                |
| **Neuromuscular**          | Motoneurone disease                                    |
| **Dysfunctional breathing**|                                                        |
| **Chest wall deformity**   |                                                        |

PRIMARY CARE RESPIRATORY JOURNAL  www.thepcj.org
A woman with breathlessness: a practical approach to diagnosis and management

- Community acquired pneumonia tends to present with symptoms developing over days, but may be more insidious in the elderly or in opportunistic infection in immunocompromised patients.
- Haemoptysis may also be a symptom of bronchiectasis. This commonly presents in a non-smoking middle-aged patient with recurrent dyspnoea, cough with purulent sputum, and is often associated with sinusitis. In one primary care study, bronchiectasis was found by high resolution CT scanning (HRCT) in 29% patients with COPD.
- Whilst weight loss can be a "red flag" symptom, weight gain can also cause an increase in breathlessness. This may be due to oedema (e.g. due to cor pulmonale) or due to obesity (defined as a Body Mass Index (BMI) >30). Obese COPD patients have increased dyspnoea at rest and poorer health status. They also have a reduction in functional residual capacity compared with non-obese subjects.
- The term dysfunctional breathing is often used synonymously with "hyperventilation syndrome" where there is over-breathing, but the term may also include irregular patterns of breathing. There is an association with symptoms of light headedness, tingling in the hands, anxiety and a feeling of inability to hold one's breath.
- Drug therapy may exacerbate breathlessness either by a direct cardiac/pulmonary toxic effect (e.g. amiodarone) or indirectly by increasing cardiac load (e.g. non-steroidal anti-inflammatory drugs, NSAIDs).

Examination
The examination will be directed by the history, but should include a general examination including searching for anaemia, looking for clubbing and lymphadenopathy as well as full pulmonary and cardiovascular examinations.

Investigations
There will be specific investigations as guided by the clinical history (e.g. sputum sample for suspected TB, D-Dimer testing for suspected thromboembolic disease) but in this lady it will be important to check post-bronchodilator spirometry, CXR, and electrocardiogram. Blood tests should include full blood count, thyroid function, C-reactive protein and/or erythrocyte sedimentation rate (ESR). Some primary care centres may have direct access to HRCT scanning if there is suspected bronchiectasis, though the high dose of radiation involved means that a clear indication will be needed.

Referral and subsequent management
Urgent referral will be needed if there is a clinical or radiological suspicion of malignancy, if tuberculosis is suspected, or if there is high suspicion of pulmonary embolism. Our patient does not have any reasons for urgent referral, but specialist advice may be still needed if there is suspicion of interstitial lung disease, concern about cardiac disease, if there is diagnostic doubt, or if a second opinion is requested by the patient. Other conditions may warrant discussion with a specialist (e.g. thyrotoxicosis) but can generally be treated in primary care.

Subsequent management will depend on the diagnosis of the co-morbid condition and management of the COPD according to national guidelines.

What might be the problem from the perspective of a resource limited setting?
COPD is rarely diagnosed in resource-limited primary care settings, where the acronym ‘COPD’ is hardly known by the people. Few health workers have the knowledge and capacity to diagnose COPD and manage it. Patients who present with respiratory problems in primary care facilities are usually assessed for tuberculosis or other infectious problems, and if found negative are referred to as “TB negative”; little more is then done for these patients until the condition is advanced.

Despite this, COPD is emerging as a major public health problem in low and middle income countries (LMIC). A study in urban areas of South Africa found a prevalence of 22.2% in males and 16.7% in females, and in Rwanda it was 9.6%. A recent study in rural Uganda found a prevalence of 16.2% affecting mainly young people in their thirties.

At secondary and tertiary healthcare facilities a cardiac problem is usually the first diagnosis considered in patients with breathlessness. Because COPD may co-exist with cardiovascular disease, this may delay assessment of COPD until patients cardiovascular management shows little improvement.

However, the history presented in this case scenario of a prior diagnosis of COPD in a current smoker with worsening breathlessness over a couple of months and recent increase in symptoms may suggest COPD exacerbation, COPD progression, or a co-morbid condition – especially the commonly encountered infectious pulmonary diseases such as tuberculosis and pneumonia. Each diagnostic possibility should be tested using information from history, physical examination and tests, though the limited range of tests available in resource limited settings increases the reliance on a thorough history and physical examination.

Is it an exacerbation of COPD?
A COPD exacerbation is defined as “an acute event characterised by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variation and leads to change in medications.” The worsening symptoms are usually cough, sputum production and breathlessness.

The initial focus should be on whether the patient is the right ‘host’ for a COPD exacerbation. Consider risk factors such as advancing age, productive cough, and longer duration since COPD diagnosis and history of exacerbations in the previous year. Past medical history can help identify pre-existing comorbidities (chronic heart failure, ischaemic heart disease and diabetes mellitus) known to increase the risk of COPD exacerbation. It has been shown in longitudinal follow-up studies that the most significant predictor of a future COPD exacerbation is the number of exacerbations in the previous year. However, in LMICs these may not have been recognised as such. Therefore any hospitalisation with respiratory illness may be considered as a surrogate of COPD exacerbation.

The next issue to consider is identification of a precipitating...
factor for exacerbation. Usual precipitants are respiratory infection and environmental pollution. In LMICs common pollutants include dust, car fumes, biomass smoke exposure, and fumes from paraffin lamps used for lighting.

**Is it progression of COPD?**
COPD disease progression could also be responsible for the worsening symptoms over the past few months. It is important to check whether our patient has quit smoking. COPD is generally a progressive disease and progression is worse with continued exposure to tobacco or biomass fuels.

**Is it a co-morbid condition?**
Differential diagnoses such as ischaemic heart disease, heart failure, lung cancer, pulmonary embolism and pulmonary artery hypertension should be considered although these tend to be less common in LMIC. On the other hand tuberculosis, pneumonia and HIV-associated pulmonary infections especially *Pneumocystis jirovecii* pneumonia (PJP) are commonly seen.

An electrocardiogram, echocardiogram and other tests can be done depending on the clinical findings, and level of care. Generally these are not available in primary care facilities in resource-poor settings and patients will need to be referred. However, healthcare workers should always bear in mind that not all patients can reach their referral facilities because of the cost of transport among other reasons. This emphasises the need for good clinical skills locally to be able to offer care to these patients.

**Management challenges in a resource limited setting**
Management of COPD presents challenges in resource-limited settings because of limited availability of tests to assess severity and drugs. Clinical assessment consisting of pulse rate, blood pressure, respiratory rate, listening to the chest, level of consciousness and orientation may be all that is available to guide immediate treatment.

Arterial blood gases are not readily available, though in some facilities oximetry can be done. Therefore, judgment of oxygen need and severity of airflow obstruction should be based on ability to speak in full sentences, use of accessory muscles of respiration, respiratory rate, and extent of wheezes on chest auscultation.

An electrocardiogram, echocardiogram and other tests can be done depending on the clinical findings, and level of care. Generally these are not available in primary care facilities in resource-poor settings and patients will need to be referred. However, healthcare workers should always bear in mind that not all patients can reach their referral facilities because of the cost of transport among other reasons. This emphasises the need for good clinical skills locally to be able to offer care to these patients.

**Management challenges in a resource limited setting**
Management of COPD presents challenges in resource-limited settings because of limited availability of tests to assess severity and drugs. Clinical assessment consisting of pulse rate, blood pressure, respiratory rate, listening to the chest, level of consciousness and orientation may be all that is available to guide immediate treatment.

**MANAGEMENT CHALLENGES IN A RESOURCE LIMITED SETTING**

Management of COPD presents challenges in resource-limited settings because of limited availability of tests to assess severity and drugs. Clinical assessment consisting of pulse rate, blood pressure, respiratory rate, listening to the chest, level of consciousness and orientation may be all that is available to guide immediate treatment.

Arterial blood gases are not readily available, though in some facilities oximetry can be done. Therefore, judgment of oxygen need and severity of airflow obstruction should be based on ability to speak in full sentences, use of accessory muscles of respiration, respiratory rate, and extent of wheezes on chest auscultation.

An electrocardiogram, echocardiogram and other tests can be done depending on the clinical findings, and level of care. Generally these are not available in primary care facilities in resource-poor settings and patients will need to be referred. However, healthcare workers should always bear in mind that not all patients can reach their referral facilities because of the cost of transport among other reasons. This emphasises the need for good clinical skills locally to be able to offer care to these patients.

**A secondary care approach to dyspnoea**

Although it is tempting to attribute the patient’s symptoms of worsening dyspnoea to her known COPD, it is imperative to conduct a thorough and meticulous history and physical examination to exclude other possible causes of the patient’s symptoms. With a careful history and examination, it is usually possible to generate a focussed differential diagnosis and to confirm the most likely diagnosis with a small number of appropriately selected investigations. The initial danger in this case would be to assume the patient’s symptoms are entirely attributable to her COPD.
A woman with breathlessness: a practical approach to diagnosis and management

before such an assessment has been completed.

Clinical history
COPD is a progressive condition that normally leads to a predictable worsening of dyspnoea with age and time (between exacerbations). Therefore, any sub-acute worsening of dyspnoea that is out of keeping of the slowly progressive pattern of COPD would be concerning for other pathologies, especially cardiac, pulmonary or systemic disorders:

- Systemic conditions such as thyroid disease and anaemia should have been excluded in primary care.
- Cardiac disease might be suggested by an exertional component to the dyspnoea (often without chest pain, the so-called “angina variant”) or a past medical history of known heart disease, but additional cardiac risk factors should be sought (hypertension, diabetes, family history etc). Paroxysmal nocturnal dyspnoea and orthopnoea might point to cardiac failure; it is important to consider that ankle swelling is not specific for left heart failure and does not exclude right heart failure secondary to COPD. Palpitations are not specific for left heart disease and might point to atrial arrhythmias, a well-recognised complication of COPD independent of atrial distension, pulmonary hypertension or lung function.47 Higher p wave dispersion (the difference between maximum and minimum p wave duration measurable on an ECG) suggests increased atrial stress as a precursor to atrial arrhythmias.
- The widest differential is in additional pulmonary disorders. Copious sputum production and recurrent infections (with/without haemoptysis) might suggest bronchiectasis complicating the COPD, persistent low-grade infective systemic and pulmonary symptoms might suggest a non-tuberculous mycobacterial infection. A viral prodrome with predominant wheeze might suggest bronchiolitis. A more subacute than insidious progression of dyspnoea might suggest pulmonary emboli (especially if there are additional risk factors of recent immobility (including long-haul travel), previous embolic disease, family history of thrombo-embolism or known malignancy or parenchymal lung disease, but a small pneumothorax is also possible. Pleurisy or pleural symptoms might suggest pleural disease as a consequence of pleural infection or malignancy. The latter may also be suggested by ‘red flag’ symptoms such as haemoptysis, weight loss and lethargy. Ankle swelling with presyncope and progressive dyspnoea without infective symptoms should prompt consideration of secondary pulmonary hypertension. Finally, an elevated Nijmegen Score67 or Epworth Score68 might point to hyperventilation or obstructive sleep apnoea, respectively.

A careful focused history should allow generation of a narrowed down list of differential diagnoses to account for the patient’s deterioration, and this will include progression of their known COPD as the final explanation.

Clinical examination
Clinical examination should ideally confirm or narrow down the differential diagnosis suggested by the history. Signs of thyroid disease and anaemia are readily apparent if looked for.

Cardiac disease might be suggested by the presence of atrial fibrillation, a displaced apex, valvular disease and signs of left heart failure including a gallop rhythm, a third heart sound and bilateral crackles, with features of right heart failure co-existent in severe cases.

Additional pulmonary disease beyond COPD is more challenging to detect. An elevated BMI and narrow oropharynx might suggest obstructive sleep apnoea. Finger clubbing might suggest malignancy (look for supraclavicular adenopathy and cachexia); bronchiectasis or fibrosis, crackles might point to either bronchiectasis (if coarse) or fibrosis (if fine and end-inspiratory). Wheeze might suggest occult malignancy (if monophonic, predominantly inspiratory or stridulous) or bronchiolitis (if associated with ‘squawks’). Stony dullness to percussion or a pleural rub points to pleural disease. A loud pulmonary component and exaggerated splitting of the second heart sound (P2) plus isolated signs of right heart failure (elevated jugular venous pressure, tricuspid regurgitation, a right ventricular gallop, hepatomegaly and ankle oedema) suggest secondary pulmonary hypertension. Tracheal deviation is concerning for either malignancy or pneumothorax.

Investigations
Investigations should ideally confirm the diagnosis suggested by the history and examination and are dictated by the findings.

- For systemic disease, thyroid function and full blood count may be confirmatory.
- For cardiac disease an ECG and echocardiogram are usually indicated, the latter clarifying (if the ECG is non-diagnostic) any pulmonary hypertension (a dilated left atrium in the setting of pulmonary hypertension points to left heart disease, a normal left atrium suggests the pulmonary hypertension is secondary to COPD). If an angina variant is possible, either an exercise test (often not possible in COPD) or myocardial perfusion scan might be done to look for reversible ischemia that might warrant revascularisation. The ECG may also show p wave depolarisation.69
- For lung disease, exercise oximetry can be very helpful (significant lung disease typically leads to desaturation). A CXR helps to confirm heart failure, pleural disease (effusion or pneumothorax), malignancy, lung infection and fibrosis, and might suggest pulmonary hypertension (enlarged interlobar pulmonary arteries with oligemia70) or more severe bronchiectasis. Milder cases of bronchiectasis or pulmonary hypertension would require HRCT (helpful for bronchiolitis too) and echocardiography respectively. True bronchiectasis can only be diagnosed on the HRCT when the patient is clinically stable: infection can cause a false positive “pseudobronchiectasis” due to airway traction.71 Pulmonary emboli usually require a CT pulmonary angiogram as a VQ scan will be indeterminate in our patient due to ventilation defects from the COPD.70 Spirometry might be used to exclude restrictive causes and prompt the need for full lung function tests (pulmonary vascular disease and interstitial lung disease both reduce gas transfer: the latter also reduces total lung capacity and residual volume. Overnight oximetry might be used to confirm sleep apnoea and a
hyperventilation provocation test for hyperventilation. A diagnosis of hyperventilation should never be made before excluding significant pulmonary vascular disease.

**Chronic thromboembolic pulmonary hypertension**

An increasingly common scenario is patients with a history of pulmonary embolism who remain breathless despite six months anticoagulation, or who present to their general practitioner having finished their anticoagulation (typically 12-24 months after the initial clot) breathless again. After excluding recurrent embolism, these patients require referral for active consideration of chronic thromboembolic pulmonary hypertension (CTEPH).

CTEPH is the only definitively treatable cause of pulmonary hypertension. It occurs in approximately 4% of patients in a 2-year period following an acute pulmonary embolus and 10% of those with recurrent pulmonary emboli. Risk factors include a previous pulmonary embolism (especially if idiopathic and large), young age, a large perfusion defect and a high clot burden.

Clinical suspicion is key, since gas transfer and the echo may not show typical abnormalities in early disease. CT pulmonary angiography may show signs of pulmonary hypertension, chronic thrombus and residual webs but no acute embolism. Unexplained presyncope with breathlessness and signs of a right ventricular strain and right heart failure would be concerning for significant pulmonary hypertension.

Without surgical treatment (pulmonary endarterectomy), CTEPH has a poor prognosis with an 80% 2-year mortality (if mean pulmonary artery pressure is greater than 50mmHg). Even 5-year mortality is 65% with lower pressures of 30mmHg. With surgery, 3-year mortality decreases to 6% or less, once the perioperative period is survived (perioperative mortality only 5%).

**Handling editor** Hilary Pinnock

**Conflicts of interest** AK has been on the advisory boards or speaker bureau for Astra Zeneca, Boehringer Ingelheim, Aerocrine, Grifols, Pfizer, Purdue, Novartis and Takeda.

KG-J has spoken on behalf of, or acted as a consultant for, Almirall, Chiesi. AstraZeneca, Glaxo Smith Kline, Novartis, Napp/Mundi Pharma. Merck, Sharp and Dohme.

FvG, BK and AM have no conflicts of interest in relation to this article.

**Contributors** AK wrote the section on differentiating respiratory and cardiac causes, and KG-J wrote the section on other causes of breathlessness. FvG and BK considered the management of breathlessness from the perspective of a resource limited setting, and AM from a secondary care perspective. The handling editor (HP) collated and edited the individual sections.

**Funding** None

**References**

1. Rutten FH, Kramer MJ, Grobbée DE, et al. Unrecognised heart failure in elderly patients with stable chronic obstructive pulmonary disease. *Eur Heart J* 2005;26:1887–94. http://dx.doi.org/10.1093/eurheartj/ehi291

2. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. *Acad Emerg Med* 2003;10:198–204. http://dx.doi.org/10.1111/j.1553-2712.2003.tb01990.x

3. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. *J Am Coll Cardiol* 2011;57:2127–38. http://dx.doi.org/10.1016/j.jacc.2011.02.020

4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2013. Available from http://www.goldcopd.org Accessed September 4, 2013

5. Hawkins N, Petrie M, Jhund P, Chalmers G, Dunn F, McMurray J. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail* 2008;10:130–5. http://dx.doi.org/10.1093/eurheartj/ehn013

6. Janssens DJ, Spruit MA, Uzko-Lencier NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. *J Palliat Med* 2011;14:735–43. http://dx.doi.org/10.1089/jpm.2010.0479

7. Walke LM, Byers AL, Tinetti ME, Dubin JA, McCorkle R, Fried TR. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. *Arch Intern Med* 2007;167:2503–8. http://dx.doi.org/10.1001/archinte.167.22.2503

8. Canosi AS, Lareux SC. Descriptors of dyspnea by patients with chronic obstructive pulmonary disease versus congestive heart failure. *Heart Lung* 2004;33:102–10. http://dx.doi.org/10.1016/j.hrtlng.2003.11.004

9. Milne EN, Bass H. Roentgenologic and functional analyses of combined chronic obstructive pulmonary disease and congestive cardiac failure. *Invest Radiol* 1969;4:129–47. http://dx.doi.org/10.1097/00002442-196905000-00001

10. Huble U, Shapiro JH. Atypical pulmonary patterns of congestive failure in chronic lung disease. The influence of pre-existing disease on the appearance and distribution of pulmonary edema. *Radiology* 1969;93:995–1006

11. Rutten FH, Moons KG, Kramer MJ, et al. Recognising heart failure in elderly patients with chronic heart failure and chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. *BMJ* 2005;331:1379. http://dx.doi.org/10.1136/bmj.38664611.58.1.55

12. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. *Eur Heart J* 2013; http://dx.doi.org/10.1093/eurheartj/eht192 (e-pub ahead of print)

13. Damarla M, Celli B, Mullerova H, Pinto-Plata V. Discrepancy in the Use of Confirmatory Tests in Patients Hospitalized With the Diagnosis of Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. *Respir Care* 2006;51:120-24

14. van Schayck OCP, Pinnock H, Ostrem A, Litt J for the IPCRG. IPCRG Consensus statement: Tackling the smoking epidemic -practical guidance for primary care. *Prim Care Respir J* 2008;17:185-93. http://dx.doi.org/10.3132/pcrj.2008.00060

15. Villar Alvarez E, Méndez Bálion M, de Miguel Díez J. Chronic obstructive pulmonary disease and heart failure. *Arch Bronconeumol* 2005;41:387–93. http://dx.doi.org/10.1016/S0300-2896(05)74818-8

16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. *Eur Heart J* 2008;29:2388–44. http://dx.doi.org/10.1093/eurheartj/ehn309

17. Forth R, Montgomery H. ACE in COPD: a therapeutic target? *Thorax* 2003;58:556–9. http://dx.doi.org/10.1136/thorax.58.7.556

18. Rutten FH, Kramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? *Eur J Heart Fail* 2008;10:706–11. http://dx.doi.org/10.1016/j.ejheart.2006.01.010

19. Dobler, C, Wong K, Marks G. Associations between statins and COPD: a systematic review. *BMJ Pulmonary Medicine* 2009;9:32. http://dx.doi.org/10.1186/1471-2466-9-32

20. The Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. *J Card Fail* 2006;12:10–38. http://dx.doi.org/10.1016/j.cardfail.2005.12.001

21. Groote P, Isard R, Assajag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT Reco survey. *Eur J Heart Fail* 2007;9:1205–11. http://dx.doi.org/10.1016/j.ejheart.2007.09.008

22. Groote P, Isard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology: The Impact-Reco Programme. *Eur J Heart Fail* 2009;11:85–91. http://dx.doi.org/10.1038/eurjhf.2009.55

23. Komajda M, Follath F, Swedberg K, et al. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. *Eur Heart J* 2003;24:464–74. http://dx.doi.org/10.1016/S0195-668X(02)00700-5

24. Ashrafian H, Violatis AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. *Prim Care Respir J* 2005;14:79–86. http://dx.doi.org/10.1016/j.pcrj.2004.09.002
A woman with breathlessness: a practical approach to diagnosis and management

2005;14:236-41. http://dx.doi.org/10.1016/j.rcpj.2005.06.005

25. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardiotoxic effects of beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97:1094-101. http://dx.doi.org/10.1016/S0954-6111(03)00186-9

26. van der Woude HI, Zaaqema J, Postma DS, et al. Determinants of effects of beta-blockers in COPD: a concern for non-selective beta-blockers. Chest 2005;127:818-24. http://dx.doi.org/10.1378/chest.127.3.818

27. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta-blockers in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-21. http://dx.doi.org/10.1378/chest.125.6.2309

28. Au DH, Uddis EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964-9. http://dx.doi.org/10.1378/chest.123.6.1964

29. Hirono O, Kubota I, Minamihaba O, et al. Left ventricular diastolic dysfunction in patients with bronchial asthma with long-term oral beta2-adrenoceptor agonists. Am Heart J 2001;142:611. http://dx.doi.org/10.1067/mhj.2001.118117

30. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. http://dx.doi.org/10.1056/NEJMoa063070

31. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (summit) study protocol. Eur Respir J 2013;41:1017-22. http://dx.doi.org/10.1183/09031936.0083712

32. Ogale SS, Lee TA, Au DH, Boubou LM, Sullivan SD. Cardiovascular events associated with pranoprol bromide in COPD. Chest 2010;137:19-19. http://dx.doi.org/10.1378/chest.08-2367

33. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. Art No.: CD009285. http://dx.doi.org/10.1002/14651858.CD009285.pub2

34. Tashkin DP, Celli B, Senn S, et al. Randomized controlled trials of shorter-acting beta-agonist in patients with chronic obstructive pulmonary disease. N Engl J Med 2003;349:1491-501. http://dx.doi.org/10.1056/NEJMoa0303342

35. National Institute for Health and Clinical Excellence. Venous thromboembolic death in COPD: a concern for non-selective beta-blockers. Thorax 2009;64 Suppl ii:i55. http://dx.doi.org/10.1136/thx.2009.121434

36. Tashkin DP, Celli B, Senn S, et al. Randomized controlled trials of shorter-acting beta-agonist in patients with chronic obstructive pulmonary disease. N Engl J Med 2003;349:1491-501. http://dx.doi.org/10.1056/NEJMoa0303342

37. Lim WS, Baqueron S, George RC. British Thoracic Society Guideline for the management of community pneumonia in adults. Thorax 2009;64 Suppl ii:i55. http://dx.doi.org/10.1136/thx.2009.121434
67. Garsen B, Colla P, Van Dixhoorn J, et al. Het herkennen van het hyperventilatiesyndroom. Medisch Contact 1984; 35:1122-4.
68. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-5.
69. Medford AR. Arrhythmias in COPD: consider P-wave dispersion and pulmonary hypertension, too. Chest 2013; 143:579. http://dx.doi.org/10.1378/chest.12-2199
70. Wijesuriya S, Chandratreya L, Medford AR. Chronic pulmonary emboli and radiologic mimics on CT pulmonary angiography: a diagnostic challenge. Chest 2013; 143:1460-71. http://dx.doi.org/10.1378/chest.12-1384
71. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension after pulmonary embolism. Am J Med 2004; 150:2257-64. http://dx.doi.org/10.1016/j.amjmed.2004.03.041
72. van Beek E, Elliot C, Kielty D. Diagnosis and initial treatment of patients with suspected pulmonary thromboembolism. Contemp Educ Anaesth Crit Care Pain 2009; 9:119-24. http://dx.doi.org/10.1093/ijaceaccpm/kp016
73. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983; 143:429-33. http://dx.doi.org/10.1001/archinte.1983.00350030039007
74. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol 1987; 17:207-9. http://dx.doi.org/10.1016/0167-5273(87)90132-X
75. Milne EN. Correlation of physiologic findings with chest roentgenology. Radiol Clin North Am 1973; 11:27-47.